Upgrade to SI Premium - Free Trial

Citizens Reiterates Market Outperform Rating on Foghorn Therapeutics (FHTX)

March 17, 2026 5:27 AM
Citizens analyst Silvan Tuerkcan reiterated a Market Outperform rating and $9.00 price target on Foghorn Therapeutics (NASDAQ: FHTX).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments